[3]Paz-Ares L,Dvorkin M,Chen Y,et al.Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN):a randomised,controlled,open-label,phase 3 trial.Lancet.2019 Nov...
参考文献：Kien Hung Do et al, PD-L1-negative non-small cell lung cancer harbouring a rare BRAF mutation with successful treatment of first-line pembrolizumab plus chemotherapy: A case report and review the literature, Respirol Case Rep. 2023 May 3.
原文出处:Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) 来源:生物谷 关于我们: 广州中医药大学金沙洲医院是广州市卫...
EurekAlert报道:近日,上海交通大学附属胸科医院陆舜教授团队在SCIENCE CHINA Life Sciences (《中国科学:生命科学》英文版) 发表题为“Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge”的综述文章。 该文深入介绍了PD-1/PD-L1抑制剂治疗非小细胞肺癌及小细胞肺...
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022 Jun;23(6):781-792. [9]onclive.com/view/front...
3. L. Paz-Ares et al., Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394, 1929-1939 (2019).4. K. Emancipator, Keytruda and PD-L1: a ...
6.Garon E B, Rizvi N A, Hui R, et al. Pembrolizumab for the treatment of non–small-cell lung cancer[J]. New England Journal of Medicine, 2015, 372(21): 2018-2028.7.Reck M, Rodríguez–Abreu D, Robinson A G, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-...
近期在《柳叶刀》发表的研究文章《First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study》表明，与化疗相比...
《Cancer》:Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death-ligand 1 ≥50% 编辑推荐: 这篇研究聚焦晚期非小细胞肺癌(NSCLC)伴脑转移且程序性死亡配体 1(PD-L1)≥50% 的患者。发现一线西米普利单抗(cemi...
11.Wang J, Zhou C, Yao W, et al. CAPSTONE-1 Study Group. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022...